Artiva Biotherapeutics financials
$7.03−0.28%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $251.0K |
| Gross profit | $0.00 | $251.0K |
| Gross margin | — | 100.0% |
| Operating income | -$89.8M | -$67.3M |
| Net income | -$83.9M | -$65.4M |
| Net margin | — | −26045.0% |
| Diluted EPS | $-3.43 | $-5.81 |
| EBITDA | -$87.2M | -$64.9M |
| Operating cash flow | -$76.8M | -$55.0M |
| Free cash flow | -$79.3M | -$55.7M |
| Diluted shares | 24.4M | 11.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $26.7M | $40.2M |
| Short-term investments | $81.3M | $145.2M |
| Total debt | $44.0K | $166.0K |
| Total assets | $130.9M | $209.6M |
| Total liabilities | $21.0M | $22.9M |
| Shareholders' equity | $110.0M | $186.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology